Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NYSE:AORT

Artivion Q3 2026 Earnings Date & Estimates

Artivion logo
$23.03 -0.27 (-1.15%)
Closing price 03:59 PM Eastern
Extended Trading
$22.98 -0.05 (-0.23%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artivion is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Artivion in Q3 2026

Artivion is expected to post earnings of -$0.0613 per share on revenue of $120.98 million. In the same quarter a year earlier Artivion reported $0.16 per share on revenue of $113.39 million. Artivion last reported on August 6, 2026, posting $0.13 per share and beating the $0.0025 consensus estimate. Artivion has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0613
Expected Revenue
$120.98 million
Prior-Year EPS
$0.16
Prior-Year Revenue
$113.39 million
Expected EPS Growth
-138.3%
Expected Revenue Growth
+6.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.13 (Beat by +$0.1275)
Last Quarter Revenue
$125.76 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Artivion Q3 2026 Earnings FAQ

Artivion (NYSE:AORT) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Artivion's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Artivion to post earnings of -$0.0613 per share for Q3 2026.

The consensus revenue estimate for Artivion is $120.98 million for Q3 2026.

Artivion Earnings Headlines

Artivion (NYSE:AORT) Research Coverage Started at Jefferies Financial Group
October 23 at 2:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148269
Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the rest
October 22, 2026  |  msn.comhttps://www.msn.com/en-us/technology/hardware-and-devices/medical-devices-supplies-cardiology-neurology-vascular-stocks-q2-teardown-artivion-nyse-aort-vs-the-rest/ar-AA2fOX3N
Nvidia's $550 Trillion Problem
Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Alphabet about $4.1 trillion. Microsoft about $3.8 trillion. So what would it take to repeat Nvidia's run? A 100x gain from here puts Nvidia near $550 trillion. Nothing in history has ever been worth that. Big money in Nvidia has already been made. By the people who bought it years ago. But that does not mean the AI boom is finished. It means the opportunity has moved underneath it... to the layer every AI company has to pay to use.tc pixel
October 26 at 1:00 AM  |  Decentralized Masters (Ad)
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
October 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2026-financial-results-302917362.html
Jefferies Initiates Artivion at Buy With $31 Price Target
October 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/jefferies-initiates-artivion-buy-31-111905778.html
Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’
October 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/artivion-rises-jefferies-initiates-buy-150257905.html
See More Artivion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artivion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artivion and other key companies, straight to your email.

About Artivion

Artivion (NYSE:AORT) (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care. Based in Kennesaw, Georgia, the company serves hospitals, surgeons, and patients in the United States and international markets. Patrick S. Mackin has served as the company’s chairman, president, and chief executive officer.

View Artivion Profile
Earnings Tools